← Dashboard
Stock
TECH
BIO-TECHNE CorpHealth CareLife Sciences Tools & ServicesLatest close $447 of 27 marquee funds currently hold1 CUSIP mapped
Current holders
7
27 funds tracked
Ever held
11
Current + past
New this quarter
2
Exited this quarter
1
Marquee-fund ownership over time
Feb 11, 2015Nov 13, 2019Feb 14, 2025May 15, 2026
Now
7
This quarter's activity
Current holders
Sorted by tenure (longest first)| Fund | First disclosed | Held | Entry price | Latest close | Return on entry |
|---|---|---|---|---|---|
| Bridgewater Associates re-entered | Q1 2015 | 46Q | $21 | $44 | +110% |
| Maverick Capital re-entered | Q1 2020 | 26Q | $51 | $44 | -12% |
| Citadel Advisors | Q3 2024(8Q snapshot) | 7Q | $72 | $44 | -38% |
| Two Sigma Investments | Q3 2024(8Q snapshot) | 7Q | $72 | $44 | -38% |
| AQR Capital Management | Q3 2024(8Q snapshot) | 7Q | $72 | $44 | -38% |
| Point72 Asset Management re-entered | Q4 2024(8Q snapshot) | 6Q | $72 | $44 | -38% |
| Glenview Capital | Q4 2025 | 2Q | $59 | $44 | -25% |
“Return on entry” is the price-only move from the fund's first disclosure to today — it ignores any adds, trims, or dividends. A fund that built its position over multiple quarters has a true cost basis somewhere between entry price and latest close; this figure is the upper bound.
Past holders
Funds that exited at some point| Fund | Last entry | Exited | Entry → Exit | Return |
|---|---|---|---|---|
| Millennium Management 2× in & out | Q3 2025 | Q2 2026 | → $43 | -19% |
| D.E. Shaw 2× in & out | Q3 2025 | Q1 2026 | → $58 | +9% |
| Renaissance Technologies | Q2 2025 | Q4 2025 | → $60 | +27% |
| Coatue Management | Q1 2020 | Q2 2020 | → $65 | +28% |
Insider activity
Form 4 — officers, directors, 10%+ ownersFiled within two business days of each transaction by anyone with material insider status at BIO-TECHNE Corp. Pair with the holders table above as a sanity check: heavy insider buying alongside marquee-fund accumulation is the strongest accumulation signal; heavy insider selling alongside fund exits is the strongest distribution signal.
Filings · last 30d
6
Filings · last 90d
10
Total on file
556
Recent SEC buffer
Most recent
Jun 4, 2026
30d / 90d windows measured from Jun 4, 2026 — the most recent Form 4 on file — not from today.
- Form 40000914190-26-000096Jun 4, 2026
- Form 40000914190-26-000092May 12, 2026
- Form 40000914190-26-000090May 7, 2026
- Form 40000914190-26-000089May 7, 2026
- Form 40000914190-26-000088May 7, 2026
- Form 40000914190-26-000083May 5, 2026
- Form 40000914190-26-000081Apr 24, 2026
- Form 40000914190-26-000080Apr 24, 2026
- Form 40000914190-26-000070Apr 16, 2026
- Form 40000914190-26-000067Apr 7, 2026
- Form 40000914190-26-000036Mar 4, 2026
- Form 40000914190-26-000030Feb 19, 2026
- Form 40000914190-26-000011Feb 5, 2026
- Form 40000914190-26-000009Feb 3, 2026
- Form 40000914190-25-000031Nov 5, 2025
Showing 15 of 556 recent Form 4 filings. Browse all on EDGAR ↗
Fundamentals
XBRL · BIO-TECHNE CorpAnnual figures sourced directly from BIO-TECHNE Corp's 10-K / 10-Q filings via SEC EDGAR XBRL. Latest fiscal year and the year-over-year change, with up to ten years of history.
Revenue
$1.22B
FY2025+5% YoY
Net income
$73.4M
FY2025-56% YoY
EPS (diluted)
$0.4600
FY2025-56% YoY
Free cash flow(?)
$256.55M
FY2025+9% YoY
Recent SEC filings
10-K · 10-Q · 8-K · 13D/G · proxyThe most recent material filings for BIO-TECHNE Corp — earnings, material events, ownership disclosures, proxy statements. Form 4 insider activity is shown in the panel above.
- 10-QQuarterly reportMay 6, 2026
- 8-KMaterial eventMay 6, 2026
- 8-KMaterial eventFeb 11, 2026
- 10-QQuarterly reportFeb 4, 2026
- 8-KMaterial eventFeb 4, 2026
- 10-QQuarterly reportNov 5, 2025
- 8-KMaterial eventNov 5, 2025
- DEF 14ADEFINITIVE PROXY STATEMENTSep 19, 2025
- 10-KAnnual reportAug 22, 2025
- 8-KMaterial eventAug 6, 2025
- 10-QQuarterly reportMay 8, 2025
- 8-KMaterial eventMay 7, 2025
- 8-KMaterial eventMay 6, 2025
- 8-KMaterial eventMar 4, 2025
- 10-QQuarterly reportFeb 6, 2025
Trade history
Every open→close lifecycle across tracked funds| Fund | Open date | Close date | Open price | Close price / current | Return |
|---|---|---|---|---|---|
| Bridgewater Associates | Q2 2026 | open | $43 | $50 | +15% |
| Point72 Asset Management | Q2 2026 | open | $43 | $44 | +3% |
| Glenview Capital | Q4 2025 | open | $59 | $44 | -25% |
| Maverick Capital | Q4 2025 | open | $59 | $50 | -16% |
| Bridgewater Associates | Q4 2025 | Q1 2026 | $60 | $60 | -1% |
| D.E. Shaw | Q3 2025 | Q1 2026 | $53 | $58 | +9% |
| Millennium Management | Q3 2025 | Q2 2026 | $53 | $43 | -19% |
| Maverick Capital | Q2 2025 | Q3 2025 | $48 | $53 | +12% |
| Point72 Asset Management | Q2 2025 | Q4 2025 | $48 | $59 | +23% |
| Renaissance Technologies | Q2 2025 | Q4 2025 | $47 | $60 | +27% |
| Point72 Asset Management | Q4 2024 | Q1 2025 | $72 | $65 | -9% |
| Citadel Advisors | Q3 2024 | open | $72 | $44 | -38% |
| Two Sigma Investments | Q3 2024 | open | $72 | $44 | -38% |
| D.E. Shaw | Q3 2024 | Q4 2024 | $72 | $72 | -0% |
| AQR Capital Management | Q3 2024 | open | $72 | $44 | -38% |
| Millennium Management | Q3 2024 | Q2 2025 | $72 | $48 | -33% |
| Bridgewater Associates | Q4 2021 | Q3 2024 | $123 | $72 | -42% |
| Coatue Management | Q1 2020 | Q2 2020 | $51 | $65 | +28% |
| Maverick Capital | Q1 2020 | Q3 2021 | $51 | $117 | +130% |
| Bridgewater Associates | Q4 2019 | Q1 2020 | $50 | $50 | +1% |
| Bridgewater Associates | Q2 2018 | Q2 2019 | $36 | $48 | +33% |
| Bridgewater Associates | Q3 2017 | Q1 2018 | $28 | $33 | +18% |
| Bridgewater Associates | Q4 2015 | Q2 2016 | $20 | $24 | +18% |
| Bridgewater Associates | Q1 2015 | Q3 2015 | $21 | $25 | +19% |
Caveats
- Covers only the 27 marquee funds tracked here, not the full institutional universe. A “0 holders” reading does not mean unowned.
- Heavy funds (Renaissance Technologies, Citadel Advisors, Soros Fund Management, Two Sigma Investments, D.E. Shaw, AQR Capital Management, Millennium Management, Point72 Asset Management) use 8-quarter snapshots, so their pre-2024 history is missing.
- “Current” reflects each fund's most recent 13F — filings lag the actual trade by up to 45 days; positions shown may have changed since.
- Cost = price at the entry filing date. Re-entered positions show the most recent open lot.
- Options, ADRs, and unmapped CUSIPs are excluded from the follower-backtest pipeline that produces these snapshots, so certain holding types won't appear here.